Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Decrease in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totaling 68,026 shares, a decrease of 73.9% from the December 31st total of 260,406 shares. Currently, 4.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 141,361 shares, the days-to-cover ratio is presently 0.5 days. Based on an average daily trading volume, of 141,361 shares, the days-to-cover ratio is presently 0.5 days. Currently, 4.0% of the shares of the stock are sold short.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on INDP shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen downgraded Indaptus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.06% of the company’s stock.

Indaptus Therapeutics Stock Performance

Shares of NASDAQ INDP traded down $0.19 during trading on Wednesday, reaching $2.29. The company had a trading volume of 44,447 shares, compared to its average volume of 119,019. Indaptus Therapeutics has a 52 week low of $1.65 and a 52 week high of $47.60. The business’s 50 day moving average price is $2.52 and its 200-day moving average price is $4.34. The stock has a market cap of $5.13 million, a PE ratio of -0.07 and a beta of 0.98.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.17) by $1.19. Equities analysts anticipate that Indaptus Therapeutics will post -1.79 earnings per share for the current year.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.